# Mixture of Doxycycline, ML-7 and L-NAME Restores the Pro- and Antioxidant Balance during Myocardial Infarction—In Vivo Pig Model Study

**Authors:** Iwona Bil-Lula, Wiktor Kuliczkowski, Anna Krzywonos-Zawadzka, Piotr Frydrychowski, Dominika Stygar, Kornela Hałucha, Agnieszka Noszczyk-Nowak

PMC · DOI: 10.3390/biomedicines12040784 · 2024-04-02

## TL;DR

A drug mix of doxycycline, ML-7, and L-NAME reduces heart injury in pigs by balancing oxidative stress during heart attacks.

## Contribution

A novel multi-drug therapy using low concentrations of doxycycline, ML-7, and L-NAME to stabilize oxidative balance during myocardial infarction in an in vivo pig model.

## Key findings

- The drug mix reduced oxidative stress markers like TOS, OSI, and MDA in pig heart tissue.
- The treatment increased total antioxidant capacity and reduced MMP-2 and MMP-9 activity.
- The mix decreased the release of MLC1 and BNP-26 into plasma, indicating reduced heart damage.

## Abstract

The restoration of blood flow to the ischemic myocardium inflicts ischemia/reperfusion (I/R) heart injury (IRI). The main contributors to IRI are increased oxidative stress and subsequent excessive production of ROS, increased expression of NOS and peroxinitate, activation of MMPs, and enhanced posttranslational modifications of contractile proteins, which make them more susceptible to proteolytic degradation. Since the pathophysiology of IRI is a complex issue, and thus, various therapeutic strategies are required to prevent or reduce IRI and microvascular dysfunction, in the current study we proposed an innovative multi-drug therapy using low concentrations of drugs applied intracoronary to reach microvessels in order to stabilize the pro- and antioxidant balance during a MI in an in vivo pig model. The ability of a mixture of doxycycline (1 μM), ML-7 (0.5 μM), and L-NAME (2 μM) to modulate the pro- and antioxidative balance was tested in the left ventricle tissue and blood samples. Data showed that infusion of a MIX reduced the total oxidative status (TOS), oxidative stress index (OSI), and malondialdehyde (MDA). It also increased the total antioxidant capacity, confirming its antioxidative properties. MIX administration also reduced the activity of MMP-2 and MMP-9, and then decreased the release of MLC1 and BNP-26 into plasma. This study demonstrated that intracoronary administration of low concentrations of doxycycline in combination with ML-7 and L-NAME is incredibly efficient in regulating pro- and antioxidant balance during MI.

## Linked entities

- **Proteins:** MMP2 (matrix metallopeptidase 2), MMP9 (matrix metallopeptidase 9), MLC1 (modulator of VRAC current 1)
- **Chemicals:** doxycycline (PubChem CID 54671203), ML-7 (PubChem CID 4216), L-NAME (PubChem CID 39836), NOS (PubChem CID 42625451)
- **Diseases:** myocardial infarction (MONDO:0005068)
- **Species:** Sus scrofa (taxon 9823)

## Full-text entities

- **Genes:** MMP9 (matrix metallopeptidase 9) [NCBI Gene 654325], NOS3 (nitric oxide synthase 3) [NCBI Gene 397557] {aka EC-NOS, NOS, NOSIII, cNOS, eNOS}, MLC1 (modulator of VRAC current 1) [NCBI Gene 100519843], MMP2 (matrix metallopeptidase 2) [NCBI Gene 397391] {aka MMP-2}
- **Diseases:** ischemic myocardium (MESH:D017682), microvascular dysfunction (MESH:D017566), I/R (MESH:D015427), heart injury (MESH:D006335), ischemia (MESH:D007511), Myocardial Infarction (MESH:D009203)
- **Chemicals:** MDA (MESH:D008315), Pro (MESH:D011392), L-NAME (MESH:D019331), ML-7 (MESH:C070571), MIX (-), Doxycycline (MESH:D004318)
- **Species:** Sus scrofa (pig, species) [taxon 9823]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11047935/full.md

---
Source: https://tomesphere.com/paper/PMC11047935